News
Mannatech Reports Financial Results for First Quarter 2025
Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for
GenSight Biologics Announces Approval of All Resolutions Supported by the Board of Directors at the Combined General Meeting of May 13, 2025
Regulatory News:
The Combined General Meeting of shareholders of GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and
Correction of a release from 12.05.2025 17:37 CET/CEST - Revenue for Q1 2025: 19.7 M€, up +36.5%
Sensorion Publishes Results of Combined Shareholders’ General Meeting Resolutions
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss
Molten Ventures Plc: Full year results presentation
EQS-News: Medios starts 2025 financial year successfully with significant increase in earnings
EQS-News: Daldrup & Söhne AG receives drilling contract for geothermal doublet in Prenzlau, Germany
Median Technologies to Present Scientific Posters on eyonis® LCS in Two Major Health Conferences in North America in May 2025
Regulatory News:
Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, “Median” or the “Company”), manufacturer of eyonis®, a suite of artificial intelligence (AI) powered Software
Fuller, Smith & Turner PLC: Transaction in own shares
EQS-News: Medios repositions itself for the next phase of its corporate development
EQS-Adhoc: Changes to the Medios AG Executive Board; Matthias Gärtner will leave the company
BILENDI: Q1 2024 revenues up +4.6% at €14.5 million
Northisle Commences Trading on the OTCQX Market Under the Symbol NTCPF
Northisle Copper and Gold Inc. (TSX-V: NCX) (“Northisle” or the “Company”) is pleased to announce that, effective today, the Company’s common shares will commence trading on the OTCQX® Best Market
Newron Announces Approval for Pivotal Phase III ENIGMA-TRS Program With Evenamide as Add-on Therapy in Patients With Treatment-resistant Schizophrenia (TRS)
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral
EQS-News: Verve Group SE Starts Trading on the Regulated Market of the Frankfurt Stock Exchange under the Ticker Symbol 'VRV'
EQS-News: ProCredit in Q1 advances on its growth and transformation strategy with good financial result
Fuller, Smith & Turner PLC: Transaction in own shares
Edison issues report on Baker Steel Resources Trust (BSRT)
Form 8.3 - The Vanguard Group, Inc.: Bakkavor Group plc
Form 8.3 - The Vanguard Group, Inc.: LondonMetric Property plc